Summit Therapeutics (SMMT) Debt to Equity (2019 - 2024)
Historic Debt to Equity for Summit Therapeutics (SMMT) over the last 6 years, with Q1 2024 value amounting to $2.26.
- Summit Therapeutics' Debt to Equity rose 20192.72% to $2.26 in Q1 2024 from the same period last year, while for Mar 2024 it was $2.26, marking a year-over-year increase of 20192.72%. This contributed to the annual value of $1.29 for FY2023, which is 6703.59% down from last year.
- As of Q1 2024, Summit Therapeutics' Debt to Equity stood at $2.26, which was up 20192.72% from $1.29 recorded in Q4 2023.
- Over the past 5 years, Summit Therapeutics' Debt to Equity peaked at $3.9 during Q4 2022, and registered a low of -$0.0 during Q1 2020.
- Moreover, its 4-year median value for Debt to Equity was $0.79 (2023), whereas its average is $1.24.
- In the last 5 years, Summit Therapeutics' Debt to Equity plummeted by 6703.59% in 2023 and then skyrocketed by 20192.72% in 2024.
- Over the past 4 years, Summit Therapeutics' Debt to Equity (Quarter) stood at -$0.0 in 2020, then soared by 266285.12% to $3.9 in 2022, then plummeted by 67.04% to $1.29 in 2023, then soared by 75.73% to $2.26 in 2024.
- Its Debt to Equity stands at $2.26 for Q1 2024, versus $1.29 for Q4 2023 and $0.84 for Q2 2023.